ArticleScientific reports2025
Hepatic arterial infusion chemotherapy with Folfox 4 regimen versus cisplatin and gemcitabine for locally advanced intrahepatic cholangiocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma.Discover oncology · 2026Review
- Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025.Liver cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For locally advanced intrahepatic cholangiocarcinoma (ICC), the combination of cisplatin plus gemcitabine (CisGem) is the standard first-line treatment. However, the outcome remains unsatisfied with the median overall survival (OS) of 11.7 months. We aimed to compare the effect of CisGem regimen and hepatic arterial infusion chemotherapy (HAIC) with Folfox 4 for locally advanced ICC. 97 Locally advanced ICC patients treated by CisGem regimen or HAIC with Folfox 4 in our institution from 2017 to 2019 were studied as training group. 43 locally advanced ICCs receiving CisGem chemotherapy or HAIC with Folfox 4 were investigated as validation group. The median OS was 14.5 months among 37 ICC patients from the HAIC group and 10.3 months among 60 ICC cases in the CisGem group. The median PFS in the HAIC group was 8.2 months in contrast to 5.3 months in the CisGem group. Additionally, objective response rate (ORR) in the HAIC group was markedly better than one in the CisGem group (29.7% v 5.0%). Patients from the HAIC group suffered from less AE (particularly 3-4 grade AE) than those in the CisGem group. The prediction nomogram models for OS and PFS were built respectively after Cox multivariate analysis, which were confirmed to be clinically useful by external validation cohort. These data here suggested HAIC with Folfox 4 was a potential first-line treatment option for local advanced ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.